Yellow Fever Immune Response at Single Cell Resolution
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03458780|
Recruitment Status : Completed
First Posted : March 8, 2018
Last Update Posted : November 8, 2019
|Condition or disease||Intervention/treatment|
|Healthy||Drug: Yellow Fever Vaccine|
|Study Type :||Observational|
|Estimated Enrollment :||6 participants|
|Official Title:||Single Cell Transcriptomics for Characterizing the Human Immune Response to Yellow Fever Vaccination|
|Actual Study Start Date :||August 22, 2016|
|Actual Primary Completion Date :||September 5, 2018|
|Actual Study Completion Date :||September 5, 2018|
Yellow Fever Vaccine Participant
Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
Drug: Yellow Fever Vaccine
Yellow Fever Vaccine .5 ml
Other Name: YF-Vax
- Feasibility and accuracy of inDrop RNA-Seq [ Time Frame: up to 42 days post baseline visit ]The feasibility and accuracy of inDrop RNA-Seq for distinguishing different cell types will be assessed by comparing (for concordance) cell subset population frequency and distribution values determined by inDrop RNA-seq to cell subset population frequency and distribution values determined by flow cytometry immunophenotyping, the present "gold standard" technique.
- Utility of inDrop RNA-Seq [ Time Frame: Days 0, 3, 7, 14, 42 ]The utility of inDrop RNA-Seq for characterizing an immune response will be determined by measuring cell subset frequencies and gene expression profiles at single cell resolution over time following YFV.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03458780
|United States, New York|
|The Rockefeller University|
|New York, New York, United States, 10065|
|Principal Investigator:||Brad R Rosenberg, MD, PhD||Icahn School of Medicine at Mount Sinai|